All News

CART.Safety

Novartis & BMS CAR-T Cell Trials on Hold

Jack Cush, MD

Reuters and the Wall Street Journal report that both Novartis and Bristol Myers Squibb (BMS) have paused their autoimmune disease CAR-T ce

Read Article
Cancer.risk_.jpg

EUSTAR Registry - Cancer in Systemic Sclerosis

Jack Cush, MD

Cancer is a major cause of mortality in systemic sclerosis (SSc).  A nested case-control study within EUSTAR registry shows distinct patterns of cancer related temporally to SSc, serologic profiles and traditional cancer risk factors.

Read Article
FDA%20approved2.jpg

FDA Approves Brepocitinib to Treat Dermatomyositis

Jack Cush, MD

The FDA and Priovant recently annouced approval of brepocitinib (Lisraya), a JAK1/TYK2 inhibitor, for the indication of adults with dermatomyositis (DM). This is the first oral (once daily) agent approved for DM.

Read Article
RheumNow Podcast square

NME: New Molecular Entities (8.28.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!

Read Article
PMR,flag

Secukinumab in Polymyalgia Rheumatica

Jack Cush, MD

Polymyalgia rheumatica (PMR) is a common disorder of the elderly that responds well to glucocorticoids (GC), but is plagued by an inability to wean off of GCs.

Read Article
Gottrons,mechanics

Brepocitinib Skin Outcomes in Patients With Dermatomyositis

Jack Cush, MD

A secondary analysis of the VALOR trial has shown that the TYK2/JAK1 inhibitor brepocitinib was effective at cutaneous disease activity outcomes, delivering rapid, clinically meaningful, and remission-level control of cutaneous dermatomyositis (DM).

Read Article
Monitoring%20BP_0.jpg

JAMA Review: Postural Orthostatic Tachycardia Syndrome (POTS)

Jack Cush, MD

Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance.

Read Article
Metanalysis looked at neutrophil to Lymph ration (NLR) in SLE - 31 studies, 4,006 SLE pts. NLR signif incr in SLE worldwide. NLR was higher in Active vs inactive SLE, and showed a significant but moderate correlation w/ SLEDAI (CC=0.354, p < 0.001). https://t.co/ROG5L4nfo2 https://t.co/9mqqId45lG

Links:

Dr. John Cush RheumNow ( View Tweet)
Ro52 Abs in idiopathic inflammatory myopathies (IIM). From 2,126 IIM China/Japan pts, Ro52 positivity was common (46%), esp in MDA5+ DM & anti-synthetase syndr (ASyS) & was assoc w/ high freq of ILD, rapidly progressive ILD, and poor prognosis. https://t.co/may6ZTJkvt https://t.co/EuinNbZUm7

Links:

Dr. John Cush RheumNow ( View Tweet)
Secukinumab in Polymyalgia Rheumatica PMR is a common disorder of the elderly that responds well to GC, but is plagued by an inability to wean off of GCs. The NEJM has published the results of the REPLENISH trial demonstrating that secukinumab (an interleukin-17A inhibitor) is https://t.co/ijkHKC7IWJ
Dr. John Cush RheumNow ( View Tweet)
True or False: Compared to adult systemic sclerosis, juvenile systemic sclerosis is more commonly associated with diffuse cutaneous disease and renal crisis. Test your knowledge in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/q4wlnCQsny

Links:

Dr. John Cush RheumNow ( View Tweet)
Guidelines for Adult-Onset IgA Vasculitis A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology, and pathology published evidence-based guidelines for adult-onset IgAV, which behaves very differently in adults than the usually https://t.co/12T8lJhPFe
Dr. John Cush RheumNow ( View Tweet)
Glucocorticoids: Use vs.Toxicity This review article addresses the recognition, prevention and management of GC toxicity in rheumatic patients. Despite guidelines and recommendations that GC be tapered, lowered or discontinued, they continue to be widely used with serious https://t.co/Tf8YkQ9iFB
Dr. John Cush RheumNow ( View Tweet)
True or False: A meta-analysis of 61 studies found that exercise showed anti-inflammatory trends, including reductions in CRP, IL-6, and TNF-α, in most chronic diseases. Test your knowledge in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/7MxkveOuZE

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA Review: Postural Orthostatic Tachycardia Syndrome (POTS) POTS is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance. https://t.co/dAKlTp4VK3 https://t.co/A2UvgYOQN1

Links:

Dr. John Cush RheumNow ( View Tweet)
Guidelines for Adult-Onset IgA Vasculitis A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology, and pathology published evidence-based guidelines for adult-onset IgAV, which behaves very differently in adults than the usually https://t.co/mNuL4TG9Ua
Dr. John Cush RheumNow ( View Tweet)
Age-specific Incidence of Systemic Lupus Erythematosus Epidemiologic estimates on SLE diagnosis are limited. The CDC National Lupus Registry network of population-based SLE registries has assessed and reported age-specific incidence of SLE by sex, race, and ethnicity. https://t.co/g5A7DMQIyp
Dr. John Cush RheumNow ( View Tweet)
Does exercise affect inflammatory biomarkers? Metanalysis of 61 studies shows mostly low certainty evidence of inflammation-modulating effects of exercise. In most chronic diseases, exercise showed anti-inflammatory trends w/ reductions in CRP, IL-6, TNF-α https://t.co/EP74b3mVAT https://t.co/WBTHjsCzKL

Links:

Dr. John Cush RheumNow ( View Tweet)
Ivarmacitinib (AKA SHR-0302) is a JAK1 inhib approved in China. Phase II/III RCT (NCT04481139) in active #AS Rx w/ ivarmacitinib 4 mg (n 187) or placebo (n 186) showing IVRMA @wk 12 IVRMA had signif better ASAS20 response(49% vs 29%) & ASAS40 (32% vs 18%). Also superior: total https://t.co/ilVtrQgHxR
Dr. John Cush RheumNow ( View Tweet)
Glucocorticoids: Use vs.Toxicity This review article addresses the recognition, prevention and management of GC toxicity in rheumatic patients. Despite guidelines and recommendations that GC be tapered, lowered or discontinued, they continue to be widely used with serious https://t.co/rmjoYJzCLD
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×